ID   MDA-MB-468rCDDP1000
AC   CVCL_D6VQ
SY   MDA-MB-468 rCDDP1000
RX   DOI=10.1101/2024.01.20.576412;
CC   Group: Triple negative breast cancer (TNBC) cell line.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0419 ! MDA-MB-468
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 19-12-24; Version: 2
//
RX   DOI=10.1101/2024.01.20.576412;
RA   Grimsley H.E., Antczak M., McLaughlin K.-M., Nist A., Mernberger M.,
RA   Stiewe T., Speidel D., Cox K., Cinatl J. Jr., Wass M.N., Garrett M.D.,
RA   Michaelis M.;
RT   "Resistance patterns in drug-adapted cancer cell lines reflect complex
RT   evolution in clinical tumors.";
RL   bioRxiv 2024:01.20.576412-01.20.576412(2024).
//